Sagimet Biosciences Inc. Shareholders' Equity
Sagimet Biosciences Inc. (SGMT) had Shareholders' Equity of $256.15 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-11
- 2026-06-30: Stockholders' Equity Attributable to Parent $256.15M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $102.46M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $111.38M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $119.25M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $256.15M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $102.46M 10-Q · filed 2026-08-11 |
| 2025-12-31 | $111.38M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $119.25M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $130.16M 10-Q · filed 2026-08-11 |
| 2025-03-31 | $138.99M 10-Q · filed 2026-08-11 |
| 2024-12-31 | $155.81M 10-Q · filed 2026-08-11 |
| 2024-09-30 | $170.68M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $183.29M 10-Q · filed 2025-11-13 |
| 2024-03-31 | $190.02M 10-Q · filed 2025-11-13 |
| 2023-12-31 | $91.06M 10-K · filed 2026-03-11 |
| 2023-09-30 | $97.88M 10-Q · filed 2024-11-14 |
| 2023-06-30 | -$198.41M 10-Q · filed 2024-11-14 |
| 2023-03-31 | -$192.70M 10-Q · filed 2024-11-14 |
| 2022-12-31 | -$186.95M 10-K · filed 2025-03-12 |
| 2022-09-30 | -$180.55M 10-Q · filed 2023-11-13 |
| 2022-06-30 | -$173.42M 10-Q · filed 2023-11-13 |
| 2022-03-31 | -$166.59M 10-Q · filed 2023-11-13 |
| 2021-12-31 | -$158.26M 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |